论文部分内容阅读
目的探讨硫脲嘧啶类药物治疗甲状腺功能亢进症过程中引起血白细胞减少的发生率及发生时间。方法对2001年1月~2004年5月我院确诊为甲状腺功能亢进症并门诊予硫脲嘧啶类药物治疗的患者132例进行1.5~2年的随访,期间定期复查血白细胞。结果硫脲嘧啶类药物致血白细胞减少的发生率达27.3%(36例),其中粒细胞缺乏的发生率达0.76%(1例),白细胞减少最多发生在服药后的3月内(77.27%)。结论硫脲嘧啶类抗甲状腺药物常可引起血白细胞减少,且多发生在治疗的初始阶段,少数患者可引起严重的粒细胞缺乏,必须停用,故在药物治疗期间,应密切观察血白细胞,以避免发生严重的粒细胞缺乏。
Objective To investigate the incidence and timing of thrombocytopenic purpura induced by thiouracil in the treatment of hyperthyroidism. Methods From January 2001 to May 2004 in our hospital diagnosed with hyperthyroidism and outpatient treatment of thiouracil drugs 132 patients were 1.5 to 2 years follow-up during the regular review of white blood cells. Results Thiouracil-induced leukopenia occurred in 27.3% (36 cases). The incidence of agranulocytosis was 0.76% (1 case), and leukopenia occurred within 3 months after treatment (77.27% ). Conclusion Thiouracil anti-thyroid drugs can often lead to leukopenia, and occurs in the initial stages of treatment, a small number of patients can cause severe agranulocytosis, must be discontinued, so during drug treatment, should be closely observed white blood cells, To avoid serious agranulocytosis.